/ /

Mark L. Fuerst
Staff Correspondent
Hidden chronic hepatitis C infections remain hard to detect
With the advent of new direct-acting antiviral agents, HCV treatment has greatly improved, making identification of infected individuals even more imperative.
HCV screening common but follow-up lacking in young opioid users
More effort needed to integrate screening with follow-up care to prevent spread of the virus.
Asthma, diabetes link tied to which diagnosis comes first
Association between the diseases “is complex, not just inverse,” according to researchers.
Systematic review: DAAs provide cost-effective treatment for hepatitis C
Timely treatment with direct-acting antivirals is highly cost-effective in virtually all patients infected with HCV.
Underserved HCV patients benefiting from telemedicine
An innovative telemedicine model could substantially reduce the burden of chronic hepatitis C infection.
Triple directing-acting combination treats decompensated liver disease
A combination of three drugs successfully treats HCV-infected patients with advanced liver disease.
Liver transplant recipients with HCV fare well under drug combo
Hepatitis C virus infection in liver transplant recipients can be treated with ledipasvir and sofosbuvir without ribavirin.
Study: 12 weeks therapy combination cures virtually all HCV patients
A shorter, triple DAA therapy combination is not superior to 12 weeks of sofosbuvir plus velpatasvir in chronic HCV patients, according to researchers.
HBV reactivation with direct acting antivirals for HCV is highly manageable
New study indicates early recognition of HBV-HCV co-infection can lead to prompt treatment of HBV reactivation.
Study: DAA all-oral combination successful in treating hepatitis C
Early data shows promise in “real-world” effectiveness.